首页> 美国卫生研究院文献>Oncotarget >Oxygenationon-invasive ventilation strategy and risk for intubation in immunocompromised patients with hypoxemic acute respiratory failure
【2h】

Oxygenationon-invasive ventilation strategy and risk for intubation in immunocompromised patients with hypoxemic acute respiratory failure

机译:低氧血症急性呼吸衰竭的免疫功能低下患者的增氧/无创通气策略和插管风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We investigated how the initial ventilation/oxygenation management may influence the need for intubation on the coming day in a cohort of immunocompromised patients with acute hypoxemic respiratory failure (ARF).Data from 847 immunocompromised patients with ARF were used to estimate the probability of intubation at day+1 within the first 3 days of ICU admission, according to oxygenation management. First, noninvasive ventilation (NIV) was compared to oxygen therapy whatever the administration device; then standard oxygen was compared to High Flow Nasal Cannula therapy alone (HFNC), NIV alone or NIV+HFNC. To take into account the oxygenation regimens over time and to handle confounders, propensity score weighting models were used.In the original sample, the probability of intubation at day+1 was higher in the NIV group vs oxygenation therapy (OR = 1.64, 95CI, 1.09–2.48) or vs the standard oxygen group (OR = 2.05, 95CI: 1.29–3.29); it was also increased in the HFNC group compared to standard oxygen (OR = 2.85, 95CI: 1.37–5.67). However, all these differences disappeared by handling confounding-by-indication in the weighted samples, as well as in the pooled model. Note that adjusted OR for day-28 mortality increased with the day of intubation.In this large cohort of immunocompromised patients, ventilation/oxygenation management had no impact on the probability of intubation on the coming day.
机译:我们调查了一组急性低氧血症性呼吸衰竭(ARF)免疫功能低下患者的初始通气/加氧管理可能如何影响第二天的插管需求。使用847例免疫功能低下ARF患者的数据来估算在根据充氧管理,在ICU入院的前3天内的第1天。首先,将无创通气(NIV)与氧气疗法进行比较,无论使用哪种给药装置;然后将标准氧气与单独的高流量鼻导管治疗(HFNC),单独的NIV或NIV + HFNC进行比较。为了考虑一段时间内的充氧方案并处理混杂因素,使用了倾向得分加权模型。在原始样本中,NIV组在第1天插管的可能性高于充氧治疗(OR = 1.64、95CI, 1.09–2.48)或相对于标准氧组(OR = 2.05,95CI:1.29–3.29);与标准氧相比,HFNC组的血红蛋白也增加(OR = 2.85,95CI:1.37–5.67)。但是,所有这些差异都通过处理加权样本以及合并模型中的指示混淆而消失了。请注意,经插管当天对28天死亡率的调整后OR会增加。在这一大群免疫受损患者中,通气/加氧管理对第二天插管的可能性没有影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号